Hope this holds, great way to start the weekend!!!!!
Will we see $16+ Monday AH ?
Nice close above 50 DMA today. Stock has bounced off of $10 level multiple times over the past couple of months. Is this the start of the breakout move we've been waiting for?
Harvey, Harvey, Harvey - Are you happy now??? Larry posts and the pps closes down. (YIKES!!)
1303 Interim update Monday..
We are moving now. Lets get this over $12 again.
What news is everyone waiting for on Monday? Earnings don't come out until 8/7?
Black Magic Taking Over!!
Question for the board (???) Why does Mikey refer to the TG-1303 (triplet) combo as U2 ???? As a lawyer, he should know that "U2" is a Registered Trade Mark - IMO I hope Bono isn't out "gunning" for him!!
F.D.A. Panel Recommends Approval for Gene-Altering Leukemia Treatment
If accepted, which is likely, it will be the first gene therapy ever to reach the market. “This is the beginning of something big,” a doctor said.
this 11.2 resistance level is killing me haha
TICK TICK TICK......
17 million shares now short. Sheeeesshhhhh....
Nice start to the week! Hit 11 and no morning sell off!!
Very difficult to see TGTX not making a big run north. Im not sure about you guys but awe.SOME-StockS has provided me with some pretty good trade ideas. I messed up executing some of them but thats on me.
LIFETIME OPP..LOAD UP GUYS WHILE ITS MORE THAN DIRT CHEAP! ACRX (MC $98 M) ( Cash $72 M)FDA Decision on October 12 for potential Blockbuster & P3 Readout this month for another Drug = 500%++ POTENTIAL !!! Undiscovered Stock please do your own dd and realize the MEGA Potential ! Thank You
AcelRx Pharma (ACRX)
Market Cap $97.5 Million Cash: $72 Million Price $2.15
Upcoming Major Milestones
Zalviso Phase 3 Results in July 2017 DSUVIA PDUFA Date October 12, 2017 Zalviso NDA Resubmission in Q4 2017 DSUVIA CHMP Opinion in 1H 2018 (EU Approval) Zalviso FDA approval expected in Q2 2018
There is one major catalyst set to hit press at some point during July and a subsequent catalyst slated for mid-October. If both come out as positive for the company, there is considerable upside potential on the cards. We are talking the potential to go from a $3 million revenues quarterly company to one targeting markets with a combined $1.5 billion in sales with just two drugs.
There is what we are watching out for. So, the first catalyst, the July catalyst, derives from an ongoing phase 3 study of a drug called Zalviso.
So that is the first catalyst; for the second one we have to move to the start of the final quarter, specifically, October.
In parallel to Zalviso, AcelRx is also trying to get a drug called DSUVIA approved in the US. This one is also a pain drug, this time designed for the treatment of moderate-to-severe pain in a medically supervised setting. The company submitted an NDA for the asset at the end of last year and, in February this year, the FDA accepted the submission for consideration. On acceptance, the agency set a PDUFA day of October 12, 2017, meaning it will make a decision as to whether it is willing to approve the drug before or on that date.
While Zalviso is our near-term catalyst, the DSUVIA decision probably holds more weight from a valuation perspective. Why? Because peak sales for this one are estimated at a little over $1.1 billion in the US alone. If FDA gives a green light for commercialization to the asset, therefore, the company could have a blockbuster drug on its hands. Combine that with the close to $400 million in revenues potential from Zalviso, and AcelRx could very justifiably become a multibillion-dollar biotech company before the end of the decade.
We have had some big winners over the last month or so with our Biotech Catalyst series and here is another one to take a look at. The company is AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a junior biotechnology stock-based out of California with a ma
You guys on this board should take a look at $OMER, setting up for a very nice swing. I advise getting in on a dip if possible.
Another good positive article out today on seeking alpha.